Dr Sven Kili | Vice President and Head of Gene Therapy Development
GlaxoSmithKline

Dr Sven Kili, Vice President and Head of Gene Therapy Development, GlaxoSmithKline

Dr Sven Kili is the VP and Development Head for the Cell and Gene Therapy division of GSK where he leads the teams developing ex-vivo Gene Therapies for a variety of genetic disorders. They are currently developing solutions for a number of diseases including ADA-SCID; WAS; Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy medical activities, he oversaw all UK regulatory functions and was the QPPV for the EU. Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities. He sits on the board of a Swedish Stem Cell company and still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time

Appearances:



Day 1 Orphan 14th Nov @ 14:20

Advancing innovation and the development of gene therapies through the maintenance of a collaborative approach

  • Sharing GSK’s journey in treating ADA-SCID through gene therapy: perspectives on regulation, facing challenging communities and the reputable high price

back to speakers